USFDA completes inspection at Lupin’s Indore facility
28 January 2019 | News
The inspection was carried out between January 14 and January 25, 2019
United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Pithampur Unit-2 (Indore) facility. The inspection was carried out between January 14 and January 25, 2019. The inspection at Pithampur Unit-2 (Indore) closed with 6 observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally
